Atara Bio Announces Positive Results From Phase 1 Clinical Trial of Wilms' Tumor 1 Targeted Cytotoxic T Lymphocytes (WT1-CTL) Product Candidate in Hematologic Malignancies

Loading...
Loading...
Atara Biotherapeutics, Inc.
ATRA
today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) are reporting positive Phase 1 clinical data for Atara's WT1-CTL product candidate during the 2015 ASH Annual Meeting. The findings describe the safety and activity of primary donor-derived WT1-CTLs following allogeneic hematopoietic cell transplantation (alloHCT) for the treatment of patients with relapsed-refractory multiple myeloma (MM), including plasma cell leukemia (PCL). Dr. Guenther Koehne, M.D. and colleagues are reporting positive clinical data from the ongoing Phase 1 trial: 7 patients with relapsed-refractory MM, including PCL were treated with alloHCT followed by WT1-CTLs.By one year, 3 achieved a complete remission (CR), 1 achieved a partial response (PR), 2 had stable disease (SD), and 1 had progressive disease.2 patients who developed a CR remain in remission for more than 1 year.There were no
See full press release
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...